Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Outlook Therapeutics ( (OTLK) ) has provided an update.
On June 2, 2025, Outlook Therapeutics announced the commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK. This launch marks a significant step for the company in addressing wet age-related macular degeneration (wet AMD), potentially enhancing its market position in the ophthalmology sector.
The most recent analyst rating on (OTLK) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
Spark’s Take on OTLK Stock
According to Spark, TipRanks’ AI Analyst, OTLK is a Underperform.
Outlook Therapeutics is facing critical financial challenges with no revenue and high leverage, posing substantial risks. The technical analysis shows weak momentum with mixed signals, while the valuation indicates non-profitability. These factors collectively suggest a low stock score.
To see Spark’s full report on OTLK stock, click here.
More about Outlook Therapeutics
Outlook Therapeutics operates in the biopharmaceutical industry, focusing on developing and commercializing monoclonal antibody treatments for various eye diseases.
Average Trading Volume: 469,489
Technical Sentiment Signal: Sell
Current Market Cap: $78.85M
For detailed information about OTLK stock, go to TipRanks’ Stock Analysis page.